{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_gtunptrdmeflwhaulj4q","seq":1420836,"kind":"article","title":"NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC","url":"https://www.onclive.com/view/nda-submission-is-initiated-for-zipalertinib-plus-chemotherapy-in-frontline-egfr-exon-20-insertion-nsclc","published":"2026-10-02T14:29:00Z","seen":"2026-10-02T19:59:11Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q131418163","name":"Zipalertinib","type":"other"},{"id":"Q14865565","name":"EGFR","type":"other"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_xqfzrdgyct27zowffaia","category":"health","category_p":0.58,"sentiment":"neutral","tone":-0.22,"political":0.27},{"id":"n_xqfzrdgyct27zowffaia","seq":1236551,"kind":"press_release","title":"New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program","url":"https://www.globenewswire.com/news-release/2026/10/01/3373489/0/en/new-drug-application-submission-initiated-for-zipalertinib-plus-chemotherapy-in-first-line-egfr-exon-20-insertion-mutation-nsclc-for-review-under-fda-real-time-oncology-review-prog.html","summary":"In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC","published":"2026-10-01T23:30:00Z","seen":"2026-10-01T23:33:07Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:cgem","us2300311063"],"entities":[{"id":"Q131418163","name":"Zipalertinib","type":"other"},{"id":"Q14865565","name":"EGFR","type":"other"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"mentions":2,"story":"st_xqfzrdgyct27zowffaia","category":"health","category_p":0.62,"sentiment":"neutral","tone":-0.07,"political":0.24},{"id":"n_3fql2tu6i4ezck7fz7ya","seq":546401,"kind":"press_release","title":"HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer","url":"https://www.globenewswire.com/news-release/2026/09/29/3370345/0/en/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer.html","summary":"— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —","published":"2026-09-29T00:00:00Z","seen":"2026-09-29T00:06:23Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:hcm","hkse:0013","lse:hcm","us44842l1035","kyg4672n1198"],"entities":[{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q29006526","name":"Tagrisso","type":"other"},{"id":"Q14865565","name":"EGFR","type":"other"}],"mentions":2,"story":"st_3fql2tu6i4ezck7fz7ya","category":"health","category_p":0.63,"sentiment":"neutral","tone":0.2,"political":0.16}]}